Melatonin use in managing insomnia in children with autism and other neurogenetic disorders - An assessment by the international pediatric sleep association (IPSA).

Sleep experts reviewed research on melatonin for helping children with autism and similar conditions sleep better. While melatonin is commonly prescribed for these children, there wasn't enough clear guidance for doctors. The expert panel looked at recent studies and created recommendations about how melatonin works, possible side effects, and how to use it safely.

The International Pediatric Sleep Association (IPSA) established a task force to review clinical trial literature from 2012 onwards regarding melatonin use for managing insomnia in children with autism and other neurogenetic disorders. This expert panel review was prompted by the widespread prescription of melatonin in this population despite lacking or inconclusive evidence for practical clinical guidance. The publication provides evidence summary regarding melatonin's utility and potential side effects, along with practice-related considerations and clinical insights for healthcare providers treating sleep disturbances in children with autism and neurogenetic conditions.

Represents effort to standardize melatonin prescribing practices for sleep management in autism and neurogenetic disorders. May provide evidence-based framework for clinical decision-making, though specific recommendations and evidence quality assessment are not detailed in this abstract.

This abstract describes the rationale and scope of an expert panel review but does not provide specific findings, methodology details, or quantitative results from the literature review conducted.

Though it is widely prescribed for improving sleep of children with autism and other neurogenetic disorders, there is a need for practical guidance to clinicians on the use of melatonin for managing insomnia in this population. Because data were either lacking or inconclusive, a task force was established by the International Pediatric Sleep Association (IPSA) to examine the literature based on clinical trials from 2012 onwards. A summary of evidence pertaining to melatonin's utility and potential side effects, practice-related caveats, and insights for use are published herewith.